摘要
Here, we report that TW01001, a novel piperazinedione compound, could be a new mitotic inhibitor for the treatment of non-small cell lung cancer by the following observations in A549 cells: (1) induction of cells to accumulate at G2/M phase, which ultimately led to cell apoptotic death, (2) accumulation of p53 and inhibition of survival signalings, and (3) induction of p53-independent autophagy. Taken together, our data suggested that TW01001 induces autophagy-p53-signaling pathway to cause mitotic arrest and cell growth inhibition in A549 cells and provides the framework for further development as a novel therapeutic agent for lung cancer treatment.
原文 | 英語 |
---|---|
頁(從 - 到) | 370-378 |
頁數 | 9 |
期刊 | Cancer Letters |
卷 | 336 |
發行號 | 2 |
DOIs | |
出版狀態 | 已發佈 - 8月 19 2013 |
ASJC Scopus subject areas
- 腫瘤科
- 癌症研究